Phillip Md Et Al Frost Buys 100,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 1st. The shares were acquired at an average cost of $1.65 per share, for a total transaction of $165,000.00. Following the completion of the purchase, the chief executive officer now owns 213,751,448 shares in the company, valued at $352,689,889.20. This trade represents a 0.05 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, March 28th, Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock. The stock was acquired at an average price of $1.70 per share, with a total value of $255,000.00.
• On Monday, March 17th, Phillip Md Et Al Frost acquired 200,000 shares of OPKO Health stock. The stock was bought at an average price of $1.74 per share, for a total transaction of $348,000.00.
• On Friday, February 28th, Phillip Md Et Al Frost bought 67,434 shares of OPKO Health stock. The stock was bought at an average price of $1.71 per share, with a total value of $115,312.14.
• On Tuesday, January 28th, Phillip Md Et Al Frost purchased 47,537 shares of OPKO Health stock. The shares were bought at an average price of $1.47 per share, for a total transaction of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost acquired 150,000 shares of OPKO Health stock. The stock was bought at an average price of $1.47 per share, with a total value of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.48 per share, for a total transaction of $740,000.00.

OPKO Health Stock Down 4.8 %

Shares of NASDAQ:OPK opened at $1.57 on Friday. The firm has a 50 day simple moving average of $1.69 and a 200-day simple moving average of $1.58. OPKO Health, Inc. has a twelve month low of $1.15 and a twelve month high of $2.04. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $1.05 billion, a PE ratio of -8.26 and a beta of 1.70.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The firm had revenue of $183.60 million during the quarter, compared to analysts’ expectations of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. On average, equities analysts predict that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Institutional Trading of OPKO Health

A number of large investors have recently made changes to their positions in the company. FMR LLC increased its position in OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after buying an additional 11,089 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in shares of OPKO Health by 75.3% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 12,417 shares during the last quarter. Orion Portfolio Solutions LLC acquired a new position in shares of OPKO Health in the 3rd quarter valued at $45,000. Cibc World Markets Corp purchased a new stake in OPKO Health in the 4th quarter valued at $45,000. Finally, Zacks Investment Management acquired a new stake in OPKO Health during the 4th quarter worth $49,000. 64.63% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

OPK has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of OPKO Health in a report on Wednesday, March 19th. StockNews.com upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd. Finally, Barrington Research restated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research note on Wednesday, March 12th.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.